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Abstract
Our hypothesis is that iron accumulated in tissue, rather than in serum,
may compromise cardiovascular control. Male Fischer 344 rats weigh-
ing 180 to 220 g were divided into 2 groups. In the serum iron overload
group (SIO, N = 12), 20 mg elemental iron was injected ip daily for 7
days. In the tissue iron overload group (TIO, N = 19), a smaller amount
of elemental iron was injected (10 mg, daily) for 5 days followed by a
resting period of 7 days. Reflex heart rate responses were elicited by iv
injections of either phenylephrine (0.5 to 5.0 µg/kg) or sodium nitro-
prusside (1.0 to 10.0 µg/kg). Baroreflex curves were determined and
fitted to sigmoidal equations and the baroreflex gain coefficient was
evaluated. To evaluate the role of other than a direct effect of iron on
tissue, acute treatment with the iron chelator deferoxamine (20 mg/kg,
iv) was performed on the TIO group and the baroreflex was re-
evaluated. At the end of the experiments, evaluation of iron levels in
serum confirmed a pronounced overload for the SIO group (30-fold),
in contrast to the TIO group (2-fold). Tissue levels of iron, however,
were higher in the TIO group. The SIO protocol did not produce
significant alterations in the baroreflex curve response, while the TIO
protocol produced a nearly 2-fold increase in baroreflex gain (-4.34 ±
0.74 and -7.93 ± 1.08 bpm/mmHg, respectively). The TIO protocol
animals treated with deferoxamine returned to sham levels of barore-
flex gain (-3.7 ± 0.3 sham vs -3.6 ± 0.2 bpm/mmHg) 30 min after the
injection. Our results indicate an effect of tissue iron overload on the
enhancement of baroreflex sensitivity.
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Introduction
The cardiovascular system has the cru-
cial task of supplying all body cells with their
metabolic needs. The complexity of this func-
tion demands efficient control mechanisms
for maintaining blood pressure and flux within
adequate levels in every region of the body.
An organism copes with blood fluctuations
by intrinsic, neural and humoral regulatory
mechanisms (1). Of particular interest to the
present research, neural regulatory mechan-
isms, more specifically baroreceptor feed-
back control, are characterized by their
prompt effect (1) on a beat-to-beat time scale
(2). Several pathophysiological states are
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known to alter the responsiveness of the
baroreflex response (2).
Iron overload is associated with several
pathophysiological states (e.g., hemoglobino-
pathies, hemolytic anemia, hemochromato-
sis) and behaviors such as smoking and ex-
cessive iron and vitamin C intake (3). Be-
sides the epidemiologic concern regarding
dietary iron intake, iron accumulation and its
relation to pathological processes is still the
main focus of many heated debates (4). Nev-
ertheless, iron overload has undeniably been
associated with cardiac and vascular dys-
functions in experimental conditions (5-7).
Experiments conducted ex vivo have shown
that iron overload induces a condition of
heart failure (8) in Langendorff preparations
of isolated hearts. In fact, deposition of iron
into the heart is emerging as an important
cause of heart failure (6). However, a de-
tailed study of cardiovascular reflex involve-
ment in an in vivo iron overload model has
not yet been reported. Such an investigation
could contribute to the use of iron overload
as an animal model for studying heart fail-
ure.
Iron has been associated with the modu-
lation of the metabolism and availability of
certain chemical mediators such as nitric
oxide (9-11) and carbon monoxide (12),
which are implicated in baroreflex function
both peripherally and centrally (13-15). Ni-
tric oxide as well as oxygen-derived free
radicals induced by changes in iron concen-
tration are known to suppress baroreceptor
activity particularly at high levels of arterial
pressure (15). Recent studies have demon-
strated alterations in baroreflex function aris-
ing from processes that produce free radicals
such as atherosclerosis, in which the barore-
flex gain coefficient was shown to be de-
creased (16). Although cardiac insufficiency
is more closely related to the inadequacy of
the heart to function as a pump, dysfunction
of neural feedback mechanisms (e.g., baro-
reflex) has been associated with chronic heart
failure. Increased sympathetic activity and
plasma levels of norepinephrine, parasym-
pathetic withdrawal and impaired baroreflex
gain coefficient have been reported in chronic
heart failure (17). An increased baroreflex
gain coefficient has been shown in rats with
myocardial infarction (18). Very few data
are available regarding the prognostic impli-
cations of baroreflex sensitivity and heart
rate (HR) variability for chronic heart fail-
ure. Nevertheless, both baroreflex sensitivi-
ty and HR variability have been shown to be
markedly reduced in chronic heart failure
and significantly associated with the degree
of ventricular dysfunction and with further
progression of the severity of the disease
(17). Thus, the impairment of baroreflex
function in patients with heart failure is a
well-established association. In fact, the
evaluation of baroreflex sensitivity has been
proposed as a diagnostic tool in such cases
(19).
Our hypothesis is that iron overload could
affect baroreflex function through iron accu-
mulation in the heart tissue. Therefore, the
net effect of iron overload on the baroreflex,
as demonstrated in the reports cited above,
may not be related to neural control but
rather to heart impairment. The present ex-
periment was designed to compare the effect
of circulating iron overload to that of iron
accumulated in tissues on the baroreflex of
conscious Fischer 344 rats. The effect of
acute iron chelator treatment (deferoxam-
ine) in the issue iron overload group de-
scribed above was also tested.
Material and Methods
Animals and iron overload
The study was conducted on male Fischer
344 rats weighing 180 to 210 g from the
main breeding stock of the Nutrition School,
Federal University of Ouro Preto. Animals
were kept in collective cages on a 12-h light/
dark cycle, with lights on at 7:00 am, in a
controlled-temperature environment (22 ±
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3ºC). Animals were randomly divided into
the following groups: serum iron overload
group (SIO), tissue iron overload group (TIO)
(20), and respective controls. In the SIO
protocol (N = 12), 20 mg elemental iron (0.2
ml iron dextran; Sigma, St. Louis, MO, USA)
was injected ip daily for 7 days, immediately
followed by baroreflex evaluation. In the
TIO protocol (N = 19), less elemental iron
was injected (10 mg, daily) for a shorter
period of time (5 days), followed by a resting
period of 7 days, after which the experi-
ments were conducted. Sham animals (N =
31) received placebo injections (PBS) ac-
cording to their respective iron-loaded
groups. Seven animals from the TIO proto-
col, along with their respective controls (N =
7), were separated to receive deferoxamine
mesylate (DFO, 20 mg/kg; Novartis AG,
Basel, Switzerland), in order to determine
the effect of permanent changes in barore-
flex function compared to the effect of the
direct action of iron. Efforts were made to
avoid any unnecessary distress to the ani-
mals, in accordance with the Brazilian So-
ciety for Neuroscience and Behavior Guide-
lines for Animal Experimentation.
Surgical procedures and hemodynamic
measurements
Under tribromoethanol anesthesia (250
mg/kg, ip; Aldrich Chemical Company, Inc.,
Milwaukee, WI, USA) a heat-pulled taper-
ending polyethylene catheter (PE-10 con-
nected to PE-50; Clay Adams, Parsippany,
NJ, USA) filled with heparinized PBS (125
U/ml) was positioned inside the aorta through
the left femoral artery for measurement of
pulsatile arterial pressure. A second catheter
was inserted into the inferior vena cava
through the left femoral vein for systemic
drug administration. The free endings of both
catheters were tunneled subcutaneously and
exteriorized through the back of the neck
and connected to a swivel during the experi-
ments. Pulsatile arterial pressure was meas-
ured with a pressure transducer (model
MLT0699; ADInstruments Pty Ltd., Castle
Hill, NSW Australia) connected to an ana-
log-to-digital data acquisition system (mo-
del PowerLab 400; ADInstruments). Data
were sampled at 12 bits using a 200-Hz
sampling rate. HR and mean arterial pres-
sure (MAP) were derived off-line from pul-
satile arterial pressure using the Chart for
Windows software, version 4.1.2 (ADInstru-
ments). HR and MAP variability was esti-
mated by calculating the standard deviation
of HR and MAP values within the recording
for each animal. All experiments were per-
formed approximately 24 h after surgery on
unanesthetized freely moving rats.
Baroreflex activation
Before the experiments, rats were instru-
mented and allowed to adapt to the new
environment for at least 30 min. A 20- to 30-
min recording period without any interfer-
ence was allowed to elapse in order to deter-
mine baseline MAP and HR values.
A typical recording procedure consisted
of continuously monitoring HR and MAP
while performing intravenous bolus injec-
tions of random doses of either phenyleph-
rine (0.5, 2.0, 3.5, and 5.0 µg/kg; Sigma) or
sodium nitroprusside (1.0, 4.0, 7.0, and 10.0
µg/kg; Sigma). The methodology has been
described in detail elsewhere (18). Succes-
sive drug administration was carried out only
after MAP and HR returned to baseline.
Peak values of MAP and HR in response
to phenylephrine and sodium nitroprusside
injections were used to evaluate the barore-
flex response. The data from each experi-
mental group were then organized in a two-
column table with data ordered from the
lowest to the highest MAP, along with the
respective HR values. These data were di-
vided into 10 mmHg pressure bins. For each
pressure bin, one MAP ± SEM value was
plotted against its respective HR ± SEM
value. The baroreflex curve was then fitted
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to a sigmoidal logistic equation:
HR = HRmax
  
+
     HRmin - HRmax            Eq. 1
                                    
-
  MAP - MAP50
                         
  1 + e          b
where HRmin is the lower plateau, HRmax is
the upper plateau, b is the curvature coeffi-
cient, and MAP50 is the MAP at the midpoint
of the HR range.
Individual sigmoidal functions were av-
eraged in order to determine the mean sig-
moidal fit for the group. The derivatives of
individual sigmoidal baroreflex curves were
calculated and averaged within an experi-
mental group in order to determine the baro-
reflex gain-coefficient curve.
Acute deferoximine treatment
Experiments with the chelator DFO were
carried out on 7 animals from the TIO proto-
col and respective controls (N = 7). The
baroreflex was evaluated by intravenous bo-
lus injection of sodium nitroprusside (1.0
and 4.0 µg/kg; Sigma) before and after iv
infusion of DFO (20 mg/kg). The maximal
changes in MAP and HR were evaluated and
the gain coefficient was calculated by the
equation:
Gain =
 ∆maxHR              Eq. 2
               ∆max MAP
where ∆maxMAP is the maximal change in
MAP after injection of sodium nitroprusside
and ∆maxHR is the maximal change in HR
due to the changes in MAP caused by the
pharmacological maneuver.
Determination of iron status
At the end of the experiments, a blood
sample was taken through the arterial can-
nula and centrifuged and serum separated.
Serum iron concentrations were determined
in non-hemolyzed serum samples by spec-
trophotometric analysis using commercially
available kits (# 38; Labtest, Belo Horizonte,
MG, Brazil). Immediately after blood sam-
pling, the animals were sacrificed with ethyl
ether and perfused with saline and formalde-
hyde. The liver and spleen were removed
and weighed and liver and spleen samples
were homogenized in HNO3 at 120ºC. After
evaporation of the acid, the dry residue was
resuspended in 50% hydrochloric acid (v/v)
and quantified by colorimetric analysis us-
ing orthophenanthroline (21).
Statistical analysis
Data are reported as means ± SEM. The
baroreflex curves were analyzed by one-way
analysis of variance (ANOVA) for repeated
measures. The unpaired Student t-test was
used to determine statistically significant dif-
ferences between the SIO and TIO experi-
mental groups. The paired Student t-test was
used to determine the statistically significant
differences in the TIO baroreflex gain coef-
ficient before and after DFO treatment. The
level of significance was set at P < 0.05 in all
analyses.
Results
Iron status and baseline cardiovascular
parameters
The iron status of the animals treated
with iron dextran confirmed our expecta-
tions regarding the effect of serum and tissue
iron overload on the baroreflex response
(Table 1), i.e., the SIO group presented very
high serum levels of iron (29-fold) com-
pared to the modest increase observed in the
TIO group (1.8-fold). On the other hand,
tissue accumulation (e.g., spleen and liver)
of iron was much more evident in the TIO
group, even though less iron was injected
when compared to the SIO animals.
Both iron-treated groups showed a slight,
but significant, bradycardia compared to the
sham group (SIO protocol: 341 ± 4 vs 373 ± 5




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bpm; TIO protocol: 354 ± 7 vs 373 ± 5 bpm).
However, baseline MAP values were not sig-
nificantly different between groups (Figure 1).
A slight decrease in pulse pressure was
observed in TIO rats compared to sham rats
(37.9 ± 0.92 vs 40.5 ± 0.85 mmHg, P =
0.034; data not shown). SIO rats did not
present alterations in pulse pressure when
compared with sham rats (37.0 ± 0.89 vs
38.8 ± 0.94 mmHg, P = 0.186; data not
shown). The HR time domain variability
was decreased in both iron-loaded groups
compared to the sham group (SIO protocol:
14 ± 1 vs 19 ± 2 bpm; TIO protocol: 13 ± 1 vs
19 ± 2 bpm). No statistically significant dif-
ferences were observed in MAP time do-
main variability (Figure 2).
Baroreflex
The upper panels in Figure 3 show the
MAP against HR baroreflex curve, along
with the mean sigmoidal fitting, for SIO
(Figure 3A) and TIO (Figure 3B) rats and
their respective controls. The baroreflex gain
coefficient versus pressure plot is reported
in the lower panels in Figure 3 for both SIO
(Figure 3C) and TIO (Figure 3D) animals.
The baroreflex curve for the TIO group
was shifted to the left (Figure 3B,D), closely
following the changes in resting MAP (Figure
1), as indicated by the MAP50 value. No sig-
nificant changes were observed in the barore-
flex curve of SIO rats compared to control
(Figure 3A,C). Maximal reflex tachycardia
(upper plateau) and bradycardia (lower pla-
teau), and consequently HR range, for the two
iron-treated groups did not differ statistically
from control (Table 2). However, a tendency
to a reduction in both upper plateau and HR
range was noted in SIO rats when compared to
sham rats (Table 2, Figure 3A).
TIO rats presented an increased barore-
flex gain-coefficient (1.6-fold over control)
with a concomitant narrowing of the curve
accompanied by a shift to lower MAP values
(Table 2, Figure 3B,D).
M
A
P
 t
im
e 
do
m
ai
n 
va
ria
bi
lit
y
(m
m
H
g)
5
4
3
2
1
H
R
 t
im
e 
do
m
ai
n 
va
ria
bi
lit
y
(b
pm
)
25
20
15
10
5
0
0
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
12345
**
Figure 2. Time domain variabili-
ty for mean arterial pressure (A)
and heart rate (B) in sham (open
bar, N = 24), tissue iron over-
load (hatched bar, N = 19) and
serum iron overload (filled bar,
N = 12) rats over a period of 10
min at the beginning of the re-
cordings. Data are reported as
means ± SEM. MAP = mean
arterial pressure; HR = heart
rate. *P < 0.05 compared to
the sham group (Student t-
test).
Table 1. Iron status of sham, serum iron overload and tissue iron overload rats.
Parameter Sham SIO TIO
Serum iron (µmol/l) 35.6 ± 1.97 1032.3 ± 209.68* 64.9 ± 3.94*+
Liver iron (µmol/organ) 46.6 ± 9.49 91.3 ± 15.8* 164.7 ± 10.74*+
Spleen iron (µmol/organ) 20.6 ± 1.20 19.7 ± 2.00 30.1 ± 1.20*+
Data are reported as means ± SEM for 8 rats in each group. SIO = serum iron
overload; TIO = tissue iron overload.
*P < 0.05 compared to the sham group; +P < 0.05 compared to the SIO group
(Student t-test).
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Figure 1. Baseline mean arterial
pressure (A) and heart rate (B)
of sham (open bar, N = 24), tis-
sue iron overload (hatched bar,
N = 19) and serum iron over-
load (filled bar, N = 12) rats over
a period of 10 min at the begin-
ning of the recordings. Data are
reported as mean ± SEM. *P <
0.05 compared to the sham
group (Student t-test).
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Figure 3. The upper panels (A
and B) show peak values of
mean arterial pressure and heart
rate after baroreflex stimulation
with phenylephrine and sodium
nitruprusside. The broken lines
and open circles represent iron-
treated rats and the continuous
line and filled circles represent
sham rats. The data for serum
iron overload (SIO) rats are illus-
trated in the panels on the left (A
and C) and the data for tissue
iron overload (TIO) rats are illus-
trated in the panels on the right
(B and D). The logistic sigmoi-
dal-fitting baroreceptor curve is
the mean of ten sigmoids fitted
from the data for conscious SIO
rats (N = 12), TIO rats (N = 12)
and respective sham (N = 12)
rats. The lower panels indicate
baroreflex gain, e.g., the first de-
rivative of the sigmoid functions,
at specific mean arterial pres-
sure values.
Table 2. Baroreflex curve parameters of sham, serum iron overload and tissue iron overload rats.
Parameter SIO TIO
Sham Iron treated Sham Iron treated
Upper plateau (bpm) 528 ± 27 473 ± 11 492 ± 11 469 ± 9
Lower plateau (bpm) 253 ± 10 254 ± 5 282 ± 5 274 ± 5
Heart rate range (bpm) 275 ± 27 218 ± 9 210 ± 13 196 ± 9
MAP50 (mmHg) 114 ± 4 117 ± 3 117 ± 1 111 ± 1*
Gain (bpm/mmHg) -4.91 ± 0.69 -4.34 ± 0.74 -5.03 ± 0.39 -7.93 ± 1.08*
Data are reported as means ± SEM for 12 rats in each group. SIO = serum iron overload; TIO = tissue iron
overload; MAP50 = mean arterial pressure at the midpoint of the heart rate range.
*P < 0.05 compared to the sham group (Student t-test).
Effects of acute deferoximine treatment
The upper panel in Figure 4 represents
the gain coefficient of the baroreflex tachy-
cardia (Equation 2) for the TIO and sham
rats. The MAP range in which the baroreflex
gain coefficient was evaluated corresponds
to the linear portion of the baroreflex curve
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(Figure 4, lower panel; copied from Figure
3B indicating the MAP range).
Infusion of the free iron chelator (DFO)
reduced the baroreflex gain values of the
TIO rats (Table 3) to control levels (5.28 ±
0.86 vs 3.57 ± 0.27 bpm/mmHg) but did not
affect the baroreflex gain coefficient in sham
animals (3.77 ± 0.40 vs 3.66 ± 0.41 bpm/
mmHg) when baroreflex was evaluated by
sodium nitroprusside injection.
Discussion
In this study, we sought to determine
whether iron overload produced by intraper-
itoneal injections of iron dextran affects baro-
reflex function in conscious rats. The iron
profile of SIO and TIO rats confirmed our
expectation (Table 1) of an experimental
model that would compare the effect of high
serum iron levels with the long-term effects
of iron accumulated in tissue. The results
demonstrated that the baroreflex gain was in-
creased in TIO rats (Figure 3), whereas no
differences in baroreflex function were ob-
served in SIO rats. Furthermore, the data indi-
cate a direct effect of iron in tissue, since DFO,
a chelator, was able to reverse the phenome-
non (Figure 4). Therefore, the present data
support the view that iron overload plays a role
in the functional changes regarding the effec-
tor components of baroreflex function, as
suggested previously by others (22).
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Figure 4. General baroreflex gain elicited before (filled bar) and after (hatched bar) deferox-
amine infusion (20 mg/kg, over 20 min). Left bars indicate sham rats and right bars indicate
tissue iron overload (TIO) rats. The bottom panel is a copy of Figure 3B with the marked
area showing the linear region of the baroreflex curve in which baroreflex was tested in the
deferoxamine experiment. *P < 0.05 compared to the sham group; **P < 0.05 compared
to the TIO rats before deferoxamine infusion (Student t-test).
Table 3. Changes in heart rate, mean arterial pressure and mean gain values of baroreflex evaluated by sodium nitroprusside before and after deferoxamine
(20 mg/kg) infusion in sham and tissue iron overload rats.
Group Before DFO After DFO
1.0 µg/kg NP 4.0 µg/kg NP 1.0 µg/kg NP 4.0 µg/kg NP
∆HR ∆MAP Gain ∆HR ∆MAP Gain ∆HR ∆MAP Gain ∆HR ∆MAP Gain
Sham 79 ± 6 -20 ± 2 4.24 ± 0.43 94 ± 5 -29 ± 2 3.30 ± 0.29 81 ± 5 -21 ± 2 4.02 ± 0.45 89 ± 7 -28 ± 2 3.30 ± 0.34
TIO 86 ± 11 -14 ± 1* 6.53 ± 1.01 89 ± 9 -22 ± 2 4.08 ± 0.24 85 ± 8 -26 ± 3 3.44 ± 0.32 99 ± 11 -27 ± 2 3.71 ± 0.26
Data are reported as means ± SEM for 7 rats in each group. HR = heart rate; MAP = mean arterial pressure; DFO = deferoxamine mesylate; NP = sodium
nitroprusside; TIO = tissue iron overload.
*P < 0.01 compared to the sham group (Student t-test).
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Chronic iron overload produces heart
dysfunction in a dose-dependent manner (8),
probably resulting from the time lag neces-
sary to deposit iron in tissues. In the heart,
iron, initially deposited in the epicardium,
has a long term-effect on transmural wall
thickness (23,24). Such long-term effects do
not seem to have occurred in TIO rats since
DFO was able to acutely reverse the effect of
iron overload on the baroreflex gain coeffi-
cient. The interpretation of the short-term
and long-term effects of iron in the present
study is compromised by the lack of pub-
lished information concerning acceptable
levels of iron in the rat. Neither the border-
line levels of iron nor the exposure time
needed in order to produce iron-related dys-
functions in the cardiovascular system have
been reported. Nevertheless, several reports
have demonstrated the possible role of car-
diac iron deposition in the development of
cardiomyopathy and heart failure within the
iron overload paradigm (23,25).
On the basis of the Haber-Weiss and
Fenton reactions, iron can produce hydroxyl
radicals that might lead to oxidative stress.
Extensive reviews about the effect of iron,
even at low concentrations, on free radicals
and calcium homeostasis are available (26-
29). A dose-dependent effect of oxidative
damage in rats submitted to the iron over-
load paradigm (30) agrees with our findings
of the stronger cardiovascular effects en-
countered in TIO rats. Since deferoxamine
chelates iron ions and limits the Haber-Weiss
and Fenton reactions, preventing the forma-
tion of hydroxyl radicals, it becomes impos-
sible to dissociate a direct effect of iron on
cardiac tissue from that of free radicals. Thus,
further studies using specific free radical
scavengers should be carried out to elucidate
the mechanism by which DFO was able to
reverse the effect of the TIO protocol on the
baroreflex gain coefficient.
Factors that modulate calcium homeo-
stasis in cardiomyocytes affect both contrac-
tility and cardiac rhythm. The proper control
of calcium inward current in myocytes is
essential for normal electrical rhythms, while
its dysfunction may generate life-threaten-
ing heart arrhythmias (31) along with other
pathological conditions. Both ferrous ions
(Fe2+) and free radicals have been associated
with the impairment and breakdown of Ca2+-
ATPase proteins in the sarcoplasmic reticu-
lum of the rat heart (26). Oxidative stress has
been suggested to enhance calcium currents
through neuronal Ca2+ channels (27). The
heart has a high density of L-type Ca2+ chan-
nels, which are directly modulated by Fe2+
ions (28). In addition, myocardial Fe2+ up-
take has been reported to occur via L-type
Ca2+ channels (29), indicating a complex
interaction between calcium, iron and free
radical generation in the heart and neuronal
tissue. In synthesis, both excess of iron and
free radicals have been implicated in the
disruption of intracellular calcium homeo-
stasis (32,33) not only in cardiomyocytes but
also in neurons (34,35). Taken together, these
reports agree with the hypothesis that the
increase in baroreflex tachycardia (Figure 3)
could represent an adjustment process to
compensate for iron-induced failure in myo-
cardial function, sustaining, at least in part,
blood pressure within normal levels. In fact,
the narrowing of the baroreflex curve, the
increase in baroreflex gain coefficient and
the left shift of the MAP50 (Figure 3B and D)
suggest myocardial rather than neural dys-
function. In addition, our data from the baro-
reflex curve profiles of TIO rats very much
resemble data reported by Meyrelles and
collaborators (18) using an animal model of
heart failure induced by occlusion of the
anterior descending coronary artery. In their
study, these investigators found that although
the baroreflex gain coefficient was unaltered
after the first day of infarction, 30 days after
occlusion the baroreflex gain was signifi-
cantly exaggerated. Still regarding the above-
mentioned report, one cannot fail to notice
the striking similarities between the barore-
flex curves and gain curves presented here
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(for the SIO and TIO protocols; Figure 3)
and those of 1- and 30-day infarcted animals
(18). Nevertheless, the effects of iron over-
load on other factors that modulate calcium
homeostasis in cardiomyocytes cannot be
ruled out, such as Ca2+-ATPase pump in-
volvement, low levels of Ca2+ in the reticular
sarcoplasm, Ca2+ voltage-dependent chan-
nel sensitivity, or ryanodine receptor expres-
sion, among others (36,37).
Our results support the idea of a periph-
eral action of iron affecting baroreflex func-
tion, e.g., an iron-dependent impairment of
myocardial function associated with heart
failure, since DFO was able to reverse the
effects of altered baroreflex gain observed in
Figure 3. Bartfay and collaborators (6) re-
ported finding a decrease of baseline HR
using the Langendorff isolated heart perfu-
sion technique in iron dextran-treated mice.
Our in vivo findings and Bartfay’s ex vivo
findings for baseline HR could be due to the
same intrinsic mechanisms and could result,
at least in part, from impairment of calcium
channels due to the action of free radicals or
to a direct action of ferrous iron. The de-
crease in pulse pressure observed in TIO rats
can be interpreted as a possible consequence
of the reduction of heart strength by iron-
induced heart failure.
Our results support the hypothesis of iron-
induced heart failure as an important factor
for the development of the observed adjust-
ment in baroreflex function. The data also
indicate that the iron overload model is an
interesting in vivo model for heart failure
that is both gradual and, to some extent,
reversible. Although we do not exclude the
possibility of an involvement of free radicals
and/or iron in the adjustments of the afferent
baroreflex pathway, the data strongly indi-
cate that the baroreflex curve change is the
neural response to myocardial incapacity to
properly respond to central control.
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